JP2008535860A - 乱用抵抗性アンフェタミンプロドラッグ - Google Patents

乱用抵抗性アンフェタミンプロドラッグ Download PDF

Info

Publication number
JP2008535860A
JP2008535860A JP2008505617A JP2008505617A JP2008535860A JP 2008535860 A JP2008535860 A JP 2008535860A JP 2008505617 A JP2008505617 A JP 2008505617A JP 2008505617 A JP2008505617 A JP 2008505617A JP 2008535860 A JP2008535860 A JP 2008535860A
Authority
JP
Japan
Prior art keywords
amphetamine
lysine
pharmaceutical composition
bioavailability
auc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008505617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535860A5 (enExample
Inventor
ミックル，トラヴィス
クリッシュナン，スマ
ビショップ，バーニー
スコット モンクリエフ，ジェームス
ローダーバック，クリストファー
オーベルレンダー，ロブ
ピッカリエロ，トーマス
Original Assignee
ニュー リヴァー ファーマシューティカルズ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニュー リヴァー ファーマシューティカルズ インク． filed Critical ニュー リヴァー ファーマシューティカルズ インク．
Publication of JP2008535860A publication Critical patent/JP2008535860A/ja
Publication of JP2008535860A5 publication Critical patent/JP2008535860A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2008505617A 2005-04-08 2006-04-10 乱用抵抗性アンフェタミンプロドラッグ Pending JP2008535860A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US66938505P 2005-04-08 2005-04-08
US66938605P 2005-04-08 2005-04-08
US68117005P 2005-05-16 2005-05-16
US75654806P 2006-01-06 2006-01-06
US75995806P 2006-01-19 2006-01-19
PCT/US2006/013221 WO2006121552A2 (en) 2005-04-08 2006-04-10 Abuse-resistant amphetamine prodrugs

Publications (2)

Publication Number Publication Date
JP2008535860A true JP2008535860A (ja) 2008-09-04
JP2008535860A5 JP2008535860A5 (enExample) 2011-11-10

Family

ID=37397039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008505617A Pending JP2008535860A (ja) 2005-04-08 2006-04-10 乱用抵抗性アンフェタミンプロドラッグ

Country Status (6)

Country Link
EP (1) EP1865980A4 (enExample)
JP (1) JP2008535860A (enExample)
BR (1) BRPI0612440A2 (enExample)
CA (1) CA2603873A1 (enExample)
MX (1) MX2007012507A (enExample)
WO (1) WO2006121552A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519705A (ja) * 2010-02-16 2013-05-30 ヤゴテック アーゲー アンフェタミンおよびリスデキサンフェタミンを含む組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
WO2010042120A1 (en) 2008-10-09 2010-04-15 Archimica, Inc. Process for the synthesis of amphetamine derivatives
US20140073589A1 (en) * 2012-06-27 2014-03-13 Shire Ag Amphetamine Prodrugs
US11879019B2 (en) 2016-12-19 2024-01-23 The Regents Of The University Of California Dual-enzyme responsive peptides
WO2018118903A1 (en) 2016-12-19 2018-06-28 The Regents Of The University Of California Noncrushable pill formulatiions
ES2806995T3 (es) 2017-09-20 2021-02-19 Sandoz Ag Sales cristalinas de un profármaco de dextroanfetamina
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP2022529353A (ja) 2019-04-17 2022-06-21 コンパス パスファインダー リミテッド 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
HUE059869T2 (hu) * 2019-12-30 2023-01-28 Labomed Pharmaceutical Company S A Lizdexamfetamin-sókat tartalmazó orális oldatok
JP2023549405A (ja) 2020-11-18 2023-11-24 マインド メディシン， インコーポレイテッド 心理療法を補助するためのｍｄｍａプロドラッグ
US20250064759A1 (en) 2021-12-16 2025-02-27 Labomed Pharmaceutical Company S.A. Container comprising a lisdexamfetamine containing oral solution
EP4561528A1 (en) 2022-07-29 2025-06-04 Labomed Pharmaceutical Company S.A. Lisdexamfetamine containing oral solution

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504406A (ja) * 1999-07-14 2003-02-04 シャイア ラボラトリーズ，インコーポレイテッド 急速即時放出経口投薬形態
JP2004532863A (ja) * 2001-05-25 2004-10-28 セフアロン・インコーポレーテツド モダフィニルを含んで成る固体製剤
US20050054561A1 (en) * 2002-02-22 2005-03-10 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878187A (en) * 1972-09-11 1975-04-15 Syva Co Polypeptide derivatives of amphetamine and analogs for immunoassays
AU2004277400B2 (en) * 2003-09-30 2009-01-22 Shire Llc Pharmaceutical compositions for prevention of overdose or abuse

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504406A (ja) * 1999-07-14 2003-02-04 シャイア ラボラトリーズ，インコーポレイテッド 急速即時放出経口投薬形態
JP2004532863A (ja) * 2001-05-25 2004-10-28 セフアロン・インコーポレーテツド モダフィニルを含んで成る固体製剤
US20050054561A1 (en) * 2002-02-22 2005-03-10 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519705A (ja) * 2010-02-16 2013-05-30 ヤゴテック アーゲー アンフェタミンおよびリスデキサンフェタミンを含む組成物

Also Published As

Publication number Publication date
CA2603873A1 (en) 2006-11-16
WO2006121552A3 (en) 2007-07-05
WO2006121552A2 (en) 2006-11-16
WO2006121552A9 (en) 2007-03-08
BRPI0612440A2 (pt) 2010-11-23
EP1865980A2 (en) 2007-12-19
MX2007012507A (es) 2008-03-11
EP1865980A4 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
US7223735B2 (en) Abuse resistant lysine amphetamine compounds
US7105486B2 (en) Abuse-resistant amphetamine compounds
US7678771B2 (en) Abuse-resistant amphetamine prodrugs
JP2007507520A (ja) 過剰摂取又は乱用を防止するための薬学組成物
JP2008535860A (ja) 乱用抵抗性アンフェタミンプロドラッグ
EP1991248B1 (en) Antidepressant prodrugs
CN101193650A (zh) 抗滥用的苯丙胺前体药物
RU2445085C2 (ru) Пролекарства амфетаминов с защитой от неправильного употребления
HK1088254B (en) Abuse resistant amphetamine compounds

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120625